Pediatr Gastroenterol Hepatol Nutr.  2017 Mar;20(1):14-21. 10.5223/pghn.2017.20.1.14.

Surgery in Pediatric Crohn's Disease: Indications, Timing and Post-Operative Management

• Kim S

• KMID: 2375273
• DOI: http://doi.org/10.5223/pghn.2017.20.1.14

Abstract

Pediatric onset Crohn's disease (CD) tends to have complicated behavior (stricture or penetration) than elderly onset CD at diagnosis. Considering the longer duration of the disease in pediatric patients, the accumulative chance of surgical treatment is higher than in adult onset CD patients. Possible operative indications include perianal CD, intestinal stricture or obstruction, abdominal abscess or fistula, intestinal hemorrhage, neoplastic changes and medically untreatable inflammation. Growth retardation is an operative indication only for pediatric patients. Surgery can affect a patient's clinical course, especially for pediatric CD patient who are growing physically and mentally, so the decision should be made by careful consideration of several factors. The complex and diverse clinical conditions hinder development of a systemized treatment algorithm. Therefore, timing of surgery in pediatric CD patients should be determined with individualized approach by an experienced and well organized multidisciplinary inflammatory bowel disease team. Best long-term outcomes will require proactive post-operative monitoring and therapeutic modifications according to the conditions.

Keyword

Inflammatory bowel diseases; Crohn disease; Colorectal surgery; Child

MeSH Terms

Abdominal Abscess
Adult
Aged
Child
Colorectal Surgery
Constriction, Pathologic
Crohn Disease*
Diagnosis
Hemorrhage
Humans
Inflammation
Inflammatory Bowel Diseases
Intestinal Fistula

Reference

1. Levine A, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell RK, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 2011; 17:1314–1321.

2. Gower-Rousseau C, Vasseur F, Fumery M, Savoye G, Salleron J, Dauchet L, et al. Epidemiology of inflammatory bowel diseases: new insights from a French population-based registry (EPIMAD). Dig Liver Dis. 2013; 45:89–94.

3. El-Asmar K, El-Shafei E, Abdel-Latif M, AbouZeid A, El-Behery M. Surgical aspects of inflammatory bowel diseases in pediatric and adolescent age groups. Int J Colorectal Dis. 2016; 31:301–305.

4. Na SY, Shim JO. Biological therapy for inflammatory bowel disease in children. Pediatr Gastroenterol Hepatol Nutr. 2012; 15:13–18.

5. Lakatos PL, Golovics PA, David G, Pandur T, Erdelyi Z, Horvath A, et al. Has there been a change in the natural history of Crohn's disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977-2009. Am J Gastroenterol. 2012; 107:579–588.

6. Gupta N, Cohen SA, Bostrom AG, Kirschner BS, Baldassano RN, Winter HS, et al. Risk factors for initial surgery in pediatric patients with Crohn's disease. Gastroenterology. 2006; 130:1069–1077.

7. Hatch QM, Ratnaparkhi R, Althans A, Keating M, Neupane R, Nishtala M, et al. Is modern medical management changing ultimate patient outcomes in inflammatory bowel disease? J Gastrointest Surg. 2016; 20:1867–1873.

8. Kim HJ, Oh SH, Kim DY, Lee HS, Park SH, Yang SK, et al. Clinical characteristics and long-term outcomes of paediatric Crohn's disease: a single-centre experience. J Crohns Colitis. 2017; 11:157–164.

9. Seifarth C, Kreis ME, Gröne J. Indications and specific surgical techniques in Crohn's disease. Viszeralmedizin. 2015; 31:273–279.

10. Scott N, Hughes L. Timing of ileocolonic resection for symptomatic Crohn's disease--the patient's view. Gut. 1994; 35:656–657.

11. Bhakta A, Tafen M, Glotzer O, Ata A, Chismark AD, Valerian BT, et al. Increased incidence of surgical site infection in IBD patients. Dis Colon Rectum. 2016; 59:316–322.

12. Hansen LF, Jakobsen C, Paerregaard A, Qvist N, Wewer V. Surgery and postoperative recurrence in children with Crohn disease. J Pediatr Gastroenterol Nutr. 2015; 60:347–351.

13. Pariente B, Cosnes J, Danese S, Sandborn WJ, Lewin M, Fletcher JG, et al. Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis. 2011; 17:1415–1422.

14. Keljo DJ, Markowitz J, Langton C, Lerer T, Bousvaros A, Carvalho R, et al. Course and treatment of perianal disease in children newly diagnosed with Crohn's disease. Inflamm Bowel Dis. 2009; 15:383–387.

15. Baillie CT, Smith JA. Surgical strategies in paediatric inflammatory bowel disease. World J Gastroenterol. 2015; 21:6101–6116.

16. Alós R, Hinojosa J. Timing of surgery in Crohn's disease: a key issue in the management. World J Gastroenterol. 2008; 14:5532–5539.

17. de Zoeten EF, Pasternak BA, Mattei P, Kramer RE, Kader HA. Diagnosis and treatment of perianal Crohn disease: NASPGHAN clinical report and consensus statement. J Pediatr Gastroenterol Nutr. 2013; 57:401–412.

18. Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB. AGA technical review on perianal Crohn's disease. Gastroenterology. 2003; 125:1508–1530.

19. Halme L, Sainio AP. Factors related to frequency, type, and outcome of anal fistulas in Crohn's disease. Dis Colon Rectum. 1995; 38:55–59.

20. Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn's disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis. 2003; 9:98–103.

21. Panés J, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016; 388:1281–1290.

22. Strong S, Steele SR, Boutrous M, Bordineau L, Chun J, Stewart DB, et al. Clinical practice guideline for the surgical management of Crohn's disease. Dis Colon Rectum. 2015; 58:1021–1036.

23. Di Nardo G, Oliva S, Passariello M, Pallotta N, Civitelli F, Frediani S, et al. Intralesional steroid injection after endoscopic balloon dilation in pediatric Crohn's disease with stricture: a prospective, randomized, double-blind, controlled trial. Gastrointest Endosc. 2010; 72:1201–1208.

24. Hagel AF, Hahn A, Dauth W, Matzel K, Konturek PC, Neurath MF, et al. Outcome and complications of endoscopic balloon dilatations in various types of ileocaecal and colonic stenosis in patients with Crohn's disease. Surg Endosc. 2014; 28:2966–2972.

25. Michelassi F, Balestracci T, Chappell R, Block GE. Primary and recurrent Crohn's disease. Experience with 1379 patients. Ann Surg. 1991; 214:230–238. discussion 238-40.

26. Pfefferkorn MD, Marshalleck FE, Saeed SA, Splawski JB, Linden BC, Weston BF. NASPGHAN clinical report on the evaluation and treatment of pediatric patients with internal penetrating Crohn disease: intraabdominal abscess with and without fistula. J Pediatr Gastroenterol Nutr. 2013; 57:394–400.

27. Garcia JC, Persky SE, Bonis PA, Topazian M. Abscesses in Crohn's disease: outcome of medical versus surgical treatment. J Clin Gastroenterol. 2001; 32:409–412.

28. Kim KJ, Han BJ, Yang SK, Na SY, Park SK, Boo SJ, et al. Risk factors and outcome of acute severe lower gastrointestinal bleeding in Crohn's disease. Dig Liver Dis. 2012; 44:723–728.

29. Papi C, Gili L, Tarquini M, Antonelli G, Capurso L. Infliximab for severe recurrent Crohn's disease presenting with massive gastrointestinal hemorrhage. J Clin Gastroenterol. 2003; 36:238–241.

30. Podugu A, Tandon K, Castro FJ. Crohn's disease presenting as acute gastrointestinal hemorrhage. World J Gastroenterol. 2016; 22:4073–4078.

31. Vasseur F, Gower-Rousseau C, Vernier-Massouille G, Dupas JL, Merle V, Merlin B, et al. Nutritional status and growth in pediatric Crohn's disease: a population-based study. Am J Gastroenterol. 2010; 105:1893–1900.

32. Ruemmele FM, Veres G, Kolho KL, Griffiths A, Levine A, Escher JC, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis. 2014; 8:1179–1207.

33. Malik S, Mason A, Bakhshi A, Young D, Bishop J, Garrick V, et al. Growth in children receiving contemporary disease specific therapy for Crohn's disease. Arch Dis Child. 2012; 97:698–703.

34. Singh Ranger G, Lamparelli MJ, Aldridge A, Chong SK, Mitton SG, Albanese A, et al. Surgery results in significant improvement in growth in children with Crohn's disease refractory to medical therapy. Pediatr Surg Int. 2006; 22:347–352.

35. Yu JX, East JE, Kaltenbach T. Surveillance of patients with inflammatory bowel disease. Best Pract Res Clin Gastroenterol. 2016; 30:949–958.

36. Farraye FA, Odze RD, Eaden J, Itzkowitz SH. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010; 138:746–774. 774.e1-4

37. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362:1383–1395.

38. Hyams JS, Griffiths A, Markowitz J, Baldassano RN, Faubion WA Jr, Colletti RB, et al. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. Gastroenterology. 2012; 143:365–374.e2.

39. Buisson A, Chevaux JB, Allen PB, Bommelaer G, Peyrin-Biroulet L. Review article: the natural history of postoperative Crohn's disease recurrence. Aliment Pharmacol Ther. 2012; 35:625–633.

40. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology. 1990; 99:956–963.

41. Hashash JG, Regueiro MD. The evolving management of postoperative Crohn's disease. Expert Rev Gastroenterol Hepatol. 2012; 6:637–648.

42. Regueiro M. Management and prevention of postoperative Crohn's disease. Inflamm Bowel Dis. 2009; 15:1583–1590.

43. Domènech E, Mañosa M, Lobatón T, Cabré E. Optimizing post-operative Crohn's disease treatment. Ann Gastroenterol. 2014; 27:313–319.

44. Danese S. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut. 2012; 61:918–932.

45. Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015; 110:1324–1338.

46. de Groof EJ, Buskens CJ, Bemelman WA. Single-port surgery in inflammatory bowel disease: a review of current evidence. World J Surg. 2016; 40:2276–2282.

47. Smith NP, Ba'ath ME, Perry D, Morgan LE, Lamont GL, Baillie CT. BAPS UK inflammatory bowel disease surgical practice survey. J Pediatr Surg. 2007; 42:296–299.